PLX Share Price Performance
US$1.75
0.12 (7.36%)
84.1% undervalued intrinsic discount
US$11.00
Fair Value
Price US$1.75
AnalystConsensusTarget US$11.00
Zwfis US$4.23
Fair ValueUS$11.00
Share Pricen/a
Protalix BioTherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 75 Fair Values set on narratives written by author
PLX Community Narratives
AN
Fair Value US$11 84.1% undervalued intrinsic discount
EMA Reviews And Rare Disease Trends Will Open Global Markets
2users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
ZW
Fair Value US$4.23 58.6% undervalued intrinsic discount
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.Read more
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
ZW
US$4.23
58.6% undervalued intrinsic discount
Zwfis Fair Value
Revenue
14% p.a.
Profit Margin
20%
Future PE
29.15x
Price in 2028
US$5.11
EMA Reviews And Rare Disease Trends Will Open Global Markets
Key Takeaways Commercialization and regulatory expansion of Elfabrio, along with pipeline growth, position Protalix for recurring revenue growth and improved patient retention. Platform scalability and partner contracts enhance profitability and offer substantial upside through royalty and milestone payment opportunities.Read more
2users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AN
US$11
84.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
6.65% p.a.
Profit Margin
34.04%
Future PE
46.6x
Price in 2028
US$13.52
Trending Discussion
Recently Updated Narratives
ZW
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
Fair Value: US$4.23 58.6% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Fair Value: US$11 84.1% undervalued intrinsic discount
27 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Protalix BioTherapeutics, Inc. Key Details
About PLX
- Founded
- n/a
- Employees
- 213
- CEO
- WebsiteView website
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
